news
Resolution Therapeutics to share liver disease therapy data at AASLD
Resolution Therapeutics will present interim Phase I/II data for RTX001, an engineered Regenerative Macrophage Therapy for liver disease, at the AASLD meeting in November 2026. This first-in-human trial is evaluating the therapy's safety and tolerability.
Resolution Therapeutics will present interim Phase I/II data for RTX001, an engineered Regenerative Macrophage Therapy for liver disease, at the AASLD meeting in November 2026. This first-in-human trial is evaluating the therapy's safety and tolerability.
The architecture take
I'm always watching for anything that touches regeneration, especially when it involves the body's own repair crews. Macrophage therapy for liver disease — that's literally taking immune cells and engineering them to fix tissue. If these early safety and tolerability results look good, it's a quiet signal that more advanced cellular therapies could become a real option for organ health, not just organ replacement. My liver does so much heavy lifting for my nervous system, filtering stress hormones and keeping inflammation in check. The idea that we might eventually be able to actively regenerate it, rather than just manage decline, shifts how I think about longevity. It's not just about slowing down aging; it's about active cellular repair. What's next? Probably engineered cells for kidney or even brain repair.